Clinical Trials

CNSGastrointestinalThoracic

53 enrolled

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Phase 1 Active not recruiting

400 enrolled

DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

91 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04543188 2025-10-23

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

65 enrolled 52 charts

CNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Central Nervous System Neoplasms

NCT03374254 2024-11-21

KEYNOTE-651

116 enrolled 18 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03864042 2024-09-27

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

56 enrolled 158 charts

Melanoma

NCT04965818 2024-09-19

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05810740 2024-09-19

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

37 enrolled 25 charts

Melanoma

NCT03878719 2023-04-03

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

1 enrolled

Melanoma

NCT04759846 2023-02-21

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Phase 1 Withdrawn

Melanoma

NCT05103891 2021-12-01

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Phase 1 Unknown

14 enrolled

Melanoma

NCT01337765 2020-10-09

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

29 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

BreastGastrointestinalGynecologic

89 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01469130 2020-10-05

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

21 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT01352273 2020-09-30

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

69 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT00959127 2020-09-16

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

93 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01649336 2020-09-14

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

36 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01449058 2017-10-02

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors